Study of Naltrexone for Methamphetamine Addiction

A Pilot Trial of Naltrexone for Methamphetamine Addiction - Role of the A118G SNP

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00984360

Enrollment

Registered

2009-09-25

Start date

2009-09-30

Completion date

2012-09-30

Last updated

2013-05-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Methamphetamine Dependence

Keywords

Meth, Methamphetamine Addiction, Methamphetamine Treatment, Naltrexone, Vivitrol, A118G, OPRM1

Brief summary

The purpose of this study is to determine whether methamphetamine-dependent individuals will use less methamphetamine when treated with naltrexone. The study will also investigate whether individuals with the mu opioid receptor gene variant A118G will use less methamphetamine than individuals without A118G.

Interventions

DRUGNaltrexone

380mg extended-release, given once by intramuscular gluteal injection

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 50 Years

Healthy volunteers

Inclusion criteria

* Age between 18 and 50 years * Patient is agreeable to conditions of study and signs consent form

Design outcomes

Primary

Measure	Time frame
MA (-) Urine Samples	Twice weekly for 5 weeks

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026